Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
In investigating the role of metal ions in the pathogenesis of Huntington's disease, we examined the effects of clioquinol, a metal-binding compound currently in clinical trials for Alzheimer's disease treatment, on mutant huntingtin-expressing cells. We found that PC12 cells expressing polyglutamine-expanded huntingtin exon 1 accumulated less mutant protein and showed decreased cell death when treated with clioquinol. This effect was polyglutamine-length-specific and did not alter mRNA levels or protein degradation rates. Clioquinol treatment of transgenic Huntington's mice ( R6 / 2 ) improved behavioral and pathologic phenotypes, including decreased huntingtin aggregate accumulation, decreased striatal atrophy, improved rotarod performance, reduction of weight loss, normalization of blood glucose and insulin levels, and extension of lifespan. Our results suggest that clioquinol is a candidate therapy for Huntington's disease and other polyglutamine-expansion diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The iron chelator clioquinol is also protective (Nguyen et al. 2005).”
Citations
Cites
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Analytical profiles of drug substances
(1975) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600640947 · Cited by 1,491
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Gauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T., et al. (2003) · Nature Genetics · doi:10.1038/ng1219 · Cited by 979
Schilling, G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.397 · Cited by 753
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease
Snell, R. G., MacMillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., MacDonald, M. E., Gusella, J. F., Harper, P. S., & Shaw, D. J. (1993) · Nature Genetics · doi:10.1038/ng0893-393 · Cited by 709
Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease
Dunah, A. W., Jeong, H., Griffin, A., Kim, Y.-M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., & Krainc, D. (2002) · Science · doi:10.1126/science.1072613 · Cited by 708
Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
Xia, H., Mao, Q., Eliason, S. L., Harper, S. Q., Martins, I. H., Orr, H. T., Paulson, H. L., Yang, L., Kotin, R. M., & Davidson, B. L. (2004) · Nature Medicine · doi:10.1038/nm1076 · Cited by 652
Gunawardena, S., Her, L.-S., Brusch, R. G., Laymon, R. A., Niesman, I. R., Gordesky-Gold, B., Sintasath, L., Bonini, N. M., & Goldstein, L. S. B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00594-4 · Cited by 646
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Stipe, J., White, D., & Arsdale, E. V. (1979) · The American Journal of Nursing · doi:10.2307/3424618 · Cited by 602
Metalloenzyme-like Activity of Alzheimer's Disease β-Amyloid
Opazo, C., Huang, X., Cherny, R. A., Moir, R. D., Roher, A. E., White, A. R., Cappai, R., Masters, C. L., Tanzi, R. E., Inestrosa, N. C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206428200 · Cited by 579
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515
Oxidative stress in Huntington’s disease
Browne, S. E., Ferrante, R. J., & Beal, M. F. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00216.x · Cited by 508
Cummings, C. J., Reinstein, E., Sun, Y., Antalffy, B., Jiang, Y.-H., Ciechanover, A., Orr, H. T., Beaudet, A. L., & Zoghbi, H. Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81035-1 · Cited by 501
Cellular Toxicity of Polyglutamine Expansion Proteins
Schaffar, G., Breuer, P., Boteva, R., Behrends, C., Tzvetkov, N., Strippel, N., Sakahira, H., Siegers, K., Hayer-Hartl, M., & Hartl, F. U. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.029 · Cited by 425
Watase, K., Weeber, E. J., Xu, B., Antalffy, B., Yuva-Paylor, L., Hashimoto, K., Kano, M., Atkinson, R., Sun, Y., Armstrong, D. L., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00733-x · Cited by 359
Inefficient degradation of truncated polyglutamine proteins by the proteasome
Holmberg, C. I., Staniszewski, K. E., Mensah, K. N., Matouschek, A., & Morimoto, R. I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600426 · Cited by 289
Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity
Gafni, J., Hermel, E., Young, J. E., Wellington, C. L., Hayden, M. R., & Ellerby, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401267200 · Cited by 281
Ambrose, C. M., Duyao, M. P., Barnes, G., Bates, G. P., Lin, C. S., Srinidhi, J., Baxendale, S., Hummerich, H., Lehrach, H., Altherr, M., et al. (1994) · Somatic Cell and Molecular Genetics · doi:10.1007/bf02257483 · Cited by 278
Recovery from Polyglutamine-Induced Neurodegeneration in Conditional SCA1 Transgenic Mice
Zu, T., Duvick, L. A., Kaytor, M. D., Berlinger, M. S., Zoghbi, H. Y., Clark, H. B., & Orr, H. T. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2978-04.2004 · Cited by 262
Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles
Hilditch-Maguire, P. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2789 · Cited by 226
Experimental therapeutics in transgenic mouse models of Huntington's disease
Beal, M. F., & Ferrante, R. J. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1386 · Cited by 222
Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes.
Hurlbert, M. S., Zhou, W., Wasmeier, C., Kaddis, F. G., Hutton, J. C., & Freed, C. R. (1999) · Diabetes · doi:10.2337/diabetes.48.3.649 · Cited by 218
Heiser, V., Engemann, S., Bröcker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182426599 · Cited by 205
Jiang, H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg002 · Cited by 186
Diabetes mellitus in Huntington disease
Farrer, L. A. (1985) · Clinical Genetics · doi:10.1111/j.1399-0004.1985.tb00185.x · Cited by 170
MATTSON, M. P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.004 · Cited by 164
Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease: Implications for Treatment
Milton, N. G. N. (2004) · Drugs & Aging · doi:10.2165/00002512-200421020-00002 · Cited by 158
A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor
Pollitt, S. K., Pallos, J., Shao, J., Desai, U. A., Ma, A. A. K., Thompson, L. M., Marsh, J. L., & Diamond, M. I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00697-4 · Cited by 151
Standardization and statistical approaches to therapeutic trials in the R6/2 mouse
Hockly, E., Woodman, B., Mahal, A., Lewis, C. M., & Bates, G. P. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00185-0 · Cited by 148
Andreassen, O. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0562 · Cited by 123
Huntingtin in health and disease
Young, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17742 · Cited by 118
Meade, C. A., Deng, Y., Fusco, F. R., Del Mar, N., Hersch, S., Goldowitz, D., & Reiner, A. (2002) · Journal of Comparative Neurology · doi:10.1002/cne.10295 · Cited by 111
Ruan, Q. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh082 · Cited by 93
Storey, E., Kowall, N. W., Finn, S. F., Mazurek, M. F., & Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410320408 · Cited by 59
Richter, S. N., Parolin, C., Gatto, B., Vecchio, C. D., Brocca‐Cofano, E., Fravolini, A., Palù, G., & Palumbo, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1895-1899.2004 · Cited by 40
Id, M., Jovanović, Čolić, M. J., Mihajlovic, R., Mićić, D., Selaković, V., Ninković, M., Maličević, Ž., Rusić-Stojiljković, M., & Jovicic, A. (2001) · PubMed · Cited by 25
Polyglutamine-expanded ataxin-1 recruits Cu/Zn-superoxide dismutase into the nucleus of HeLa cells
Kim, S.-J., Kim, T. S., Kim, I. Y., Hong, S., Rhim, H., & Kang, S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01241-5 · Cited by 22
Cys redox reactions and metal binding of a Cys2His2 zinc finger
Larabee, J. L., Hocker, J. R. S., & Hanas, J. S. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.10.024 · Cited by 21
Padmanabhan, G., Becue, I., & Smith, J. B. (1990) · Analytical profiles of drug substances · doi:10.1016/s0099-5428(08)60669-3 · Cited by 18
Pérez, P. V., Flores, A., Santamarı́a, A., Ríos, C., & Galván‐Arzate, S. (1996) · PubMed · Cited by 13
DISTRIBUTION OF RADIOACTIVE CLIOQUINOL IN ANIMALS
Ogata, M., Watanabe, S., Tateishi, J., Kuroda, S., & Otsuki, S. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90559-x · Cited by 9
E.C.G. PATTERN ASSOCIATED WITH ABUSE OF HARD DRUGS
Vogelsang, A. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90558-8 · Cited by 2
Research works printed but not linked: 3
- Perez, P., Flores, A., Santamaria, A., Rios, C. & Galvan-Arzate, S. (1996) Arch. Med. Res. 27, 449-452.8987176
- Maksimovic, I. D., Jovanovic, M. D., Colic, M., Mihajlovic, R., Micic, D., Selakovic, V., Ninkovic, M., Malicevic, Z., Rusic-Stojiljkovic, M. & Jovicic, A. (2001) Vojnosanit Pregl. 58, 237-242.11548547
- Ogata, M., Watanabe, S., Tateishi, J., Kuroda, S. & Otsuki, S. (1973) Lancet 1, 1248-1249.
Cited by
Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis
Bush, A. I., & Tanzi, R. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.001 · Cited by 564
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Metabolism and functions of copper in brain
Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.01.002 · Cited by 506
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497
Microglial Activation in Stroke: Therapeutic Targets
Yenari, M. A., Kauppinen, T. M., & Swanson, R. A. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.005 · Cited by 389
Metadata
- Authors
- Nguyen, T., Hamby, A., & Massa, S. M.
- Affiliations
- San Francisco VA Medical Center (US)
- ORCID
- Massa, Stephen M.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-08-08
- Volume
- 102
- Issue
- 33
- Pages
- 11840-11845
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1187967
- OpenAlex
- W2009252276
- Cited by
- 194
- References
- 54
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 3 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 13 · 2014: 14 · 2013: 10 · 2012: 14
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- clioquinol, Huntington's disease, mutant huntingtin, polyglutamine expansion, metal ions, huntingtin aggregates, striatal atrophy, R6/2 transgenic mice, neuroprotection, lifespan extension
- MeSH terms
- Huntingtin Protein, Animals, Behavior, Animal, Blood Glucose, Body Weight, Cell Line, Disease Models, Animal, Female, Humans, Huntington Disease, Insulin, Clioquinol, Male, Mice, Transgenic, Mutation, Nerve Tissue Proteins, Nuclear Proteins, Pancreas, Peptides, RNA, Messenger, Down-Regulation, Survival Rate, Cell Death, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.